Translating research into new diabetes therapies

Scientists using centrifuge
Pipettes sitting in lab

The Indiana Biosciences Research Institute (IBRI) is poised to innovate in diabetes care through its research into the pathogenesis of type 1 and type 2 diabetes.

Specifically, researchers in the IBRI Diabetes Center are pursuing cutting-edge research into how the brain effects energy expenditure and metabolism through the neuroendocrine axis, and the role of the immune system on beta cell function.

The goal of these integrated research lines, tackling the different pathways that lead to obesity and diabetes, is to provide people living with type 1 and type 2 diabetes with a brighter future - a future that includes a better treatment, a cure or even prevention of the disease ever taking hold.

The IBRI Diabetes Center, which is led by Robert Considine, PhD, is home to the Lilly Diabetes Center of Excellence (DCOE). The Lilly DCOE is a collaboration among Eli Lilly and Company, the IBRI and the Indiana University School of Medicine. The labs that are part of the Lilly DCOE include:

IBRI Partners

Diabetes Research

1 in 10 adults around the world are living with diabetes

IBRI Diabetes Center

"We are using CRISPR screening to identify new drug therapies that can halt type 1 diabetes progression."

Erica Cai, PhD
Cai Lab

IBRI scientist working in lab

Welcome to Our Open Space Laboratories

The IBRI is a leading translational research institute that advances academic and industry science through collaboration to improve patient health outcomes.